Now I have a thorough view of the paper. Let me evaluate each rebuttal claim against the actual paper content.

---

## Summary

This paper proposes *conformalized survival counterfactual prediction*, a conformal calibration procedure for constructing lower predictive bounds (LPBs) on counterfactual survival times under general right-censored data. The key mechanism restricts calibration to uncensored treated observations, reweights via inverse probability of being in treatment group *w* and uncensored, and applies weighted conformal prediction (Lei & Candès, 2021). The paper claims marginal coverage (rather than PAC-type) and a doubly robust property. Experiments span six synthetic settings and a real NSCLC dataset.

---

## Rebuttal Assessment

### Weakness 1: "Exact" coverage label is misleading
- **Author's response:** Partially address — the authors argue "exact" refers to a structural distinction from PAC-type methods, not zero finite-sample error, and that Section 1 line 33 already couples the exactness claim with explicit error quantification.
- **Assessment:** Partially convincing. The author's technical argument is substantively correct: the method genuinely eliminates the PAC-type "empirical-vs-population approximation gap" and in the oracle weight case achieves exactly α miscoverage (as shown in the derivation chain i–iv of Eq. 1). Theorem 4.1 Eq. (4) explicitly states the residual L1 term. And the contribution bullet at line 33 reads: "We provide a distribution-free **exact guarantee** for the counterfactual prediction set **and quantify the error from weight estimation**" — this is verified in the paper and the coupling is present. However, the abstract (line 9) states "exact miscoverage guarantee" with no qualifying phrase, and Section 4.2's heading "distribution-free exact guarantee" precedes a bound with a residual error term. The framing is therefore still inconsistent across the manuscript, even if the core technical distinction is valid. The concern is downgraded but not eliminated.
- **Score impact:** Weakness downgraded

---

### Weakness 2: Setting 6 empirical undercoverage is unexplained
- **Author's response:** Partially address — the Discussion's mention of "imbalanced treatment usage proportions and high censoring rates" as causes of inaccurate γ(x) estimation is cited, and the authors promise to add a characterization of Setting 6's data properties to the main text in a revision.
- **Assessment:** Unconvincing. The promise of revision does not count as a fix. The paper (line 238–239) still only says "the average coverage rate of our method slightly falls below 1 − α in setting 6, it remains remarkably close to the target level." No mechanistic connection to Theorem 4.1's L1 term appears in the main text. The Discussion reference is generic and does not specifically address Setting 6. Since coverage is the paper's headline claim, failing to explain undercoverage in 1 of 6 settings in the main text is a persistent transparency issue.
- **Score impact:** Weakness unchanged

---

### Weakness 3: Effective sample size under high censoring is not analyzed
- **Author's response:** Acknowledge — agrees this is a valid limitation and promises a censoring-rate sensitivity experiment in revision.
- **Assessment:** Unconvincing by impact. Acknowledgment is honest but does not close the gap. The promised sensitivity analysis is absent from the submitted paper. The Discussion (line 288) mentions the directional concern ("high censoring rates may lead to inaccurate estimation of γ(x)") but provides no empirical quantification.
- **Score impact:** Weakness unchanged

---

### Weakness 4: τ optimization and calibration data independence
- **Author's response:** Refute — Section 4.1 (line 162) states "our procedure yields a prediction set that satisfies the coverage guarantee for **any τ ∈ (0, 1)**," and Theorem 4.1 is for an arbitrary fixed τ. Selecting τ* post-hoc maximizes informativeness, not coverage, so no selection bias inflates the coverage guarantee.
- **Assessment:** Convincing. Verified in the paper: line 162 states the guarantee holds for any τ ∈ (0,1), and Theorem 4.1 Eq. (4) is stated for an arbitrary fixed τ. The τ* optimization selects the largest LPB among individually valid bounds — it does not optimize the coverage rate itself. This is structurally distinct from threshold selection that exploits calibration data to inflate coverage. The original review's concern is removed.
- **Score impact:** Weakness removed

---

### Weakness 5: Cross-treatment LPB comparison overstates causal interpretation
- **Author's response:** Partially address — acknowledges the interpretive limitation and notes the Discussion implicitly signals this as future work ("accurate quantitative estimation of the causal effects between different treatment outcomes"). Promises an explicit caveat in Section 5.2 in revision.
- **Assessment:** Partially convincing. The Discussion (line 288) does mention causal effect estimation as future work, implicitly acknowledging the current method does not provide treatment effect identification. However, Section 5.2 (lines 260–261) states "a higher median LPB than those treated under IMRT, which is **consistent with VMAT's better clinical benefits**" without any inline caveat. The promise of adding such a caveat is future revision — not already in the paper. The weakness is downgraded but not eliminated.
- **Score impact:** Weakness downgraded

---

## Strengths

1. **Genuine coverage type improvement**: The structural distinction between marginal (this paper) and PAC-type coverage is real and non-trivial. Steps (i)–(iv) in Eq. (1) demonstrate that the miscoverage bound equals exactly α in the oracle case, eliminating the empirical-vs-population approximation gap that afflicts Gui et al. (2024) and Davidov et al. (2025).

2. **Doubly robust property (Theorem 4.2)**: Provides two asymptotic robustness paths (A1: consistent weight estimation; A2: consistent quantile estimation), structurally guarding against model misspecification. Equations (6) and (7) establish both marginal and approximate conditional coverage guarantees in the limit.

3. **Outlier robustness (Figure 3)**: Empirical advantage in Figure 3 is compelling — Focus and Fused (PAC-type) systematically lose coverage when survival time outliers are introduced, while the proposed method maintains ~90% coverage. This directly validates the theoretical advantage of marginal vs. PAC-type guarantees in practice.

4. **Informative LPBs**: In settings 3, 4, and 5, the proposed method achieves the highest relative LPB among methods that satisfy coverage, demonstrating it is not overly conservative.

5. **Clinically grounded real-data analysis**: LPBs align with established clinical evidence across radiotherapy and chemotherapy regimens (Figure 4) and respond correctly to known prognostic factors (Figure 5, Stage, KPS, radiomic features).

6. **τ optimization is valid**: Section 4.1 and Theorem 4.1 confirm the guarantee holds for any τ ∈ (0,1), making the τ* post-hoc selection formally sound.

---

## Weaknesses

### Fatal
None.

### Major

- **"Exact" coverage label is internally inconsistent**: The abstract (line 9) and Section 4.2 heading use "exact miscoverage guarantee" without qualification, while Theorem 4.1 Eq. (4) explicitly contains an L1 weight estimation error term. The contribution bullet (line 33) is better-phrased, coupling "exact guarantee" with "and quantify the error from weight estimation." But this coupling does not appear in the abstract. The rebuttal's defense is partially convincing — the distinction from PAC-type is genuine — but does not justify using "exact" in unqualified form in the abstract. The paper should replace unqualified "exact" throughout with "marginal" or pair it with explicit error qualification.

- **Setting 6 main-text undercoverage is unexplained**: The paper only says "slightly falls below 1 − α" with no mechanistic explanation in the main text (line 238). The Discussion's generic caution about high censoring/imbalance is not linked to Setting 6 specifically. Since coverage is the headline guarantee, undercoverage in 1 of 6 settings without explanation is a persistent transparency gap, particularly unresolved by the rebuttal.

### Minor

- **Effective sample size under high censoring is not analyzed**: Algorithm 1 Step 3 restricts to uncensored treated observations, which can drastically reduce usable calibration data. No empirical sweep over censoring rates is provided. This is a genuine operating range concern for the clinical audience, acknowledged but unaddressed in the submission.

- **Cross-treatment LPB comparison lacks causal caveat in Section 5.2**: The paper compares LPBs across VMAT and IMRT groups without explicitly stating this is a consistency check rather than a causal effect estimate. The Discussion gestures toward this gap, but Section 5.2 itself does not contain a caveat.

### Trivial
None.

---

## Nice-to-Haves

- A coverage-versus-censoring-rate sensitivity analysis (e.g., 20%–80% censoring) would directly characterize the method's operating range and would be more valuable than many of the supplementary analyses already present.
- A formal proposition comparing expected-miscoverage control (this paper) to PAC-type bound guarantees under specific distributional conditions would strengthen the theoretical contribution.

---

## Novel Insights

The most technically interesting contribution — confirmed by reading the paper — is the structural elimination of the PAC-type "empirical-vs-population approximation gap" (step (1) in Section 3's analysis of Gui et al. 2024). By reformulating the miscoverage event as a weighted expectation over uncensored treated observations, the paper avoids the empirical averaging step that prevents PAC-type methods from achieving marginal coverage. Figure 3's outlier robustness experiment makes this distinction concrete and operationally compelling: PAC-type methods fail in the tails, while marginal coverage control holds by construction. The paper would be strengthened by leading with this insight rather than burying it in the outlier experiment in Section 5.1.

---

## Suggestions

1. **Replace unqualified "exact" in the abstract and Section 4.2 heading** with "marginal" or "expected-miscoverage-controlled, up to an L1 weight estimation error term." The distinction from PAC-type guarantees is genuine and compelling — it does not need imprecise language to be publishable.
2. **Address Setting 6 in the main text**: Add Setting 6's censoring rate and treatment imbalance to Section 5.1, and explicitly connect the observed undercoverage to Theorem 4.1's L1 error term.
3. **Add a censoring rate sensitivity experiment**: Varying censoring from 20% to 80% and reporting both coverage and LPB quality would directly characterize the method's clinical operating range.
4. **Add a caveat in Section 5.2**: Explicitly state that cross-treatment LPB comparisons are consistency checks with clinical evidence, not causal effect estimates, to avoid overinterpretation.

---

## Score and Decision

**Rebuttal impact summary:**

| Weakness | Original severity | Rebuttal outcome |
|---|---|---|
| "Exact" framing | Major | Downgraded: author makes substantive technical case, but abstract remains unqualified |
| Setting 6 undercoverage | Major | Unchanged: revision promise does not count |
| Censoring sensitivity | Minor | Unchanged: acknowledged, revision promised |
| τ optimization | Minor | **Removed**: author's refutation is correct and verified in paper |
| Cross-treatment causal overstatement | Minor | Downgraded: Discussion implicitly acknowledges, Section 5.2 lacks explicit caveat |

The rebuttal resolves one minor weakness (τ optimization) and partially moderates two others ("exact" framing, cross-treatment causal interpretation). The major weaknesses — "exact" label inconsistency and Setting 6 undercoverage — persist without paper-level evidence of correction. The contribution remains a genuine and meaningful incremental advance over Davidov et al. (2025), with real coverage type improvement and strong empirical support. The resolved τ concern and partial moderation of the "exact" issue marginally justify a small upward adjustment, landing between the original 5.5 and a slightly improved 5.5. On balance, the substantive contribution and experimental quality are sufficient for acceptance at the margin, and the rebuttal did not reveal additional problems. The score is maintained at **5.5**.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>